All In Biotech

Drug Trial Radar · NCT01616758

Phase II Study of GTx024 in Women With Metastatic Breast Cancer

Phase II, Open Label Study to Examine Androgen Receptor Status and the Activity of GTx-024 Hormonal Therapy in Women With Estrogen Receptor Positive Metastatic Breast Cancer Who Have Previously Responded to Hormone Therapy

Last checked: Nov 19, 2026Latest source record: Mar 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

22

Actual

Start

Apr 2013

Primary completion

Jun 2014

Study completion Mar 2016

Sponsor

Lead sponsor
GTxIndustry
Sponsor type
Industry
First posted
Jun 12, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary efficacy analysis will be the clinical benefit at 6 months as measured by a modified Response Evaluation Criteria in Solid Tumors RECIST classification. Key secondary endpoints of objective response rate, progression free survival, time to progression, duration of response, effects on physical function, and effects on tumor progression in women with Androgen Receptor positive breast cancer will also be assessed.

Conditions

  • Metastatic Breast Cancer

Interventions

  • GTx-024 9mgDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects Treated With GTx024 With Clinical Benefit With AR Positive Breast CancerTime frame: 6 months

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • AMPM Research Clinic

    Miami, Florida

  • Illinois Cancer Care, PC

    Peoria, Illinois

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Commonwealth Hematology-Oncology

    Lawrence, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.